Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease (vol 79, pg 555, 2019)

被引：1
|
作者：
Shirley, Matt [1 ]
机构：
[1] Springer, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2019年 / 79卷 / 07期
关键词：
D O I：
10.1007/s40265-019-01111-2
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The article Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
引用
收藏
页码：791 / 791
页数：1
相关论文
共 50 条
  • [1] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Matt Shirley
    Drugs, 2019, 79 : 555 - 562
  • [2] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Shirley, Matt
    DRUGS, 2019, 79 (05) : 555 - 562
  • [3] Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Matt Shirley
    Drugs, 2019, 79 : 791 - 791
  • [4] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Sheridan M. Hoy
    Clinical Drug Investigation, 2021, 41 : 405 - 412
  • [5] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Hoy, Sheridan M.
    CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 405 - 412
  • [6] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use (vol 41, pg 405, 2021)
    Hoy, Sheridan M.
    CLINICAL DRUG INVESTIGATION, 2021, 41 (06) : 591 - 591
  • [7] Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection
    Zhang, Yang
    Hill, Adam T.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (06) : 737 - 744
  • [8] Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Sheridan M. Hoy
    Clinical Drug Investigation, 2021, 41 : 591 - 591
  • [9] Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT)
    Griffith, David E.
    Eagle, Gina
    Thomson, Rachel
    Aksamit, Timothy R.
    Hasegawa, Naoki
    Morimoto, Kozo
    Addrizzo-Harris, Doreen J.
    O'Donnell, Anne E.
    Marras, Theodore K.
    Flume, Patrick A.
    Loebinger, Michael R.
    Morgan, Lucy
    Codecasa, Luigi R.
    Hill, Adam T.
    Ruoss, Stephen J.
    Yim, Jae-Joon
    Ringshausen, Felix C.
    Field, Stephen K.
    Philley, Julie V.
    Wallace, Richard J., Jr.
    van Ingen, Jakko
    Coulter, Chris
    Nezamis, James
    Winthrop, Kevin L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (12) : 1559 - 1569
  • [10] Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex
    Swenson, Colin
    Del Parigi, Angelo
    MAYO CLINIC PROCEEDINGS, 2020, 95 (01) : 201 - 202
12345